肺癌与常见呼吸系统合并症的处理
|
摘要
肺癌患者的合并症是常见的临床问题。文章主要讨论肺癌患者合并慢性阻塞性肺疾病、肺栓塞、间质性肺疾病的临床状况及相关处理。总体来说,对于合并这3种呼吸系统疾病的肺癌患者,针对肺癌的治疗选择会受到限制,相较于无合并症者生存期更短、病死率更高。
Lung cancer comorbidity is common in patients. This review focuses on the clinical situations and treatment of patients with both lung cancer and one of the following: chronic obstructive pulmonary disease(COPD), pulmonary embolism(PE) or interstitial lung disease(ILD). Generally, these patients have more limitations on selecting cancer-related therapies, and they have shorter survival time and higher mortality than patients who had lung cancers only.
Lung cancer comorbidity is common in patients. This review focuses on the clinical situations and treatment of patients with both lung cancer and one of the following: chronic obstructive pulmonary disease(COPD), pulmonary embolism(PE) or interstitial lung disease(ILD). Generally, these patients have more limitations on selecting cancer-related therapies, and they have shorter survival time and higher mortality than patients who had lung cancers only.
引文
[1]Nilsson J,Berglund A,Bergstr?m S,et al.The role of comorbidity in the management and prognosis in nonsmall cell lung cancer:a populationbased study[J].Acta Oncologica,2017,56(7):949-956.
[2]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):a national cross-sectional study[J].Lancet(London England),2018,391(10131):1706-1717.
[3]Loganathan RS,Stover DE,Shi W,et al.Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer[J].Chest,2006,129(5):1305-1312.
[4]Yi Ys,Ban Wh,Sohng Ky.Effect of COPD on symptoms,quality of life and prognosis in patients with advanced non-small cell lung cancer[J]BMC Cancer,2018,18(1):1053.
[5]Dy Sm,Sharkey P,Herbert R,et al.Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer[J].Crit Rev Oncol Hematol,2006,59(3):218-225.
[6]Inoue T,Shiomi H,Oh Rj.Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease:special reference to survival and radiation-induced pneumonitis[J].J Radiat Res,2015,56(4):727-734.
[7]Wang J,Cao J,Yuan S,et al.Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity[J].Int J Radiat Oncol Biol Phys,2013,85(3):798-804.
[8]Takeda A,Kunieda E,Ohashi T,et al.Severe COPD Is Correlated With Mild Radiation Pneumonitis Following Stereotactic Body Radiotherapy[J].Chest,2012,141(4):858-866.
[9]Kiri VA,Soriano J,Visick G,et al.Recent trends in lung cancer and its association with COPD:an analysis using the UK GP Research Database[J].Prim Care Respir J,2010,19(1):57-61.
[10]Gao YH,Guan W J,Liu Q,et al.Impact of COPD and emphysema on survival of patients with lung cancer:A meta-analysis of observational studies[J].Respirology,2016,21(2):269-279.
[11]Grills I S,Mangona VS,Welsh R,et al.Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer[J].J Clin Oncol,2010,28(6):928-935.
[12]Mokhles S,Verstegen N,Maat AP,et al.Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy:Results from propensity score analysis[J]Lung Cancer,2015,87(3):283-289.
[13]Eapen MS,Hansbro PM,Larsson-Callerfelt AK,et al.Chronic Obstructive Pulmonary Disease and Lung Cancer:Underlying Pathophysiology and New Therapeutic Modalities[J].Drugs,201878(16):1717-1740.
[14]Troosters T,Casaburi R,Gosselink R,et al.Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med,2005,172(1):19-38.
[15]Cavalheri V,Granger C.Preoperative exercise training for patients with non-small cell lung cancer[M].Chichester,UK:John Wiley&Sons Ltd,1996.
[16]Cavalheri V,Tahirah F,Nonoyama M,et al.Exercise training for people following lung resection for non-small cell lung cancer-a Cochrane systematic review[J].Cancer Treat Rev,2014,40(4):585-594.
[17]Wiskemann J,Hummler S,Diepold C,et al.POSITIVE study:physical exercise program in non-operable lung cancer patients undergoing palliative treatment[J].BMC Cancer,2016,16(1):16:499.
[18]Edbrooke L,Aranda S,Granger CL,et al.Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer-protocol for a phase II randomised controlled trial[J]BMC Cancer,2017,17(1):663.
[19]Sin DD,Wu L,Anderson JA,et al.Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease[J].Thorax,200560(12):992-997.
[20]R ay makers A J,Mccormick N,Marra CA,et al.Do inhaled corticosteroids protect against lung cancer in patients with COPD?Asystematic review[J].Respirology,2017,22(1):61-70.
[21]S?rensen H T,Mellemkj?r L,Olsen JH,et al.Prognosis of Cancers Associated with Venous Thromboembolism[J].N Engl J Med,2000343(25):1846-1850.
[22]Li Y,Shang Y,Wang W,et al.Lung Cancer and Pulmonary Embolism:What Is the Relationship?A Review[J].J Cancer,2018,9(17):3046-3057.
[23]Ma L,Wen Z.Risk factors and prognosis of pulmonary embolism in patients with lung cancer[J].Medicine(Baltimore),2017,96(16):e6638.
[24]Christensen T D,Vad H,Pedersen S,et al.Venous thromboembolism in patients undergoing operations for lung cancer:a systematic review[J].Ann Thorac Surg,2014,97(2):394-400.
[25]Sun JM,Kim TS,Lee J,et al.Unsuspected pulmonary emboli in lung cancer patients:the impact on survival and the significance of anticoagulation therapy[J].Lung Cancer,2010,69(3):330-336.
[26]Konstantinides SV.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J].Eur Heart J,201435(43):3033-3073.
[27]MahéI,Chidiac J,Bertoletti L,et al.The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site[J].Am JMed,2017,130(3):337-347.
[28]Shinagare A B,Ok ajima Y,Ox nard GR,et al.Unsuspected pulmonary embolism in lung cancer patients:Comparison of clinical characteristics and outcome with suspected pulmonary embolism[J].Lung Cancer,2012,78(2):161-166.
[29]Zhang J,Zhang YL,Ma KX,et al.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis[J].Thorax2013,68(5):442-450.
[30]Zhang J,Zhang YL,Ma KX,et al.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis[J].Thorax2013,68(5):442-450.
[31]Fuentes HE,Oramas DM,Paz LH,et al.Meta-analysi s on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer[J].Thromb Res,2017,154:28-34.
[32]Archontogeorgis K,Steiropoulos P,Tzouvelekis A,et al.Lung Cancer and Interstitial Lung Diseases:A Systematic Review[J].Pulm Med2012,2012(1):1-11.
[33]Raghu G,Nyberg F,Morgan G.The epidemiology of interstitial lung disease and its association with lung cancer[J].Br J Cancer,2004,91Suppl 2(S2):S3-10.
[34]Miyazaki K,Satoh H,Kurishima K,et al.Interstitial lung disease in patients with small cell lung cancer[J].Med Oncol,2010,27(3):763-767.
[35]Chen H,Senan S,Nossent EJ,et al.Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease:A Systematic Review[J].Int J Radiat Oncol Biol Phys,2017,98(3):622-631.
[36]Sato T,Teramukai S,Kondo H,et al.Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer[J].J Thorac Cardiovasc Surg,2014,147(5):1604-1611.
[37]Kato T,Masuda N,Nakanishi Y,et al.Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer[J].Lung Cancer,2017,104:111-118.
[38]Tomassetti S,Gurioli C,Ryu JH,et al.The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis[J].Chest,2015,147(1):157-164.
[39]Mohamed S,Bayoumi H,El-Aziz NA,et al.Prevalence,risk factors,and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis:a study from the Middle East[J].Multidiscip Respir Med,2018,13:3.
[2]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):a national cross-sectional study[J].Lancet(London England),2018,391(10131):1706-1717.
[3]Loganathan RS,Stover DE,Shi W,et al.Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer[J].Chest,2006,129(5):1305-1312.
[4]Yi Ys,Ban Wh,Sohng Ky.Effect of COPD on symptoms,quality of life and prognosis in patients with advanced non-small cell lung cancer[J]BMC Cancer,2018,18(1):1053.
[5]Dy Sm,Sharkey P,Herbert R,et al.Comorbid illnesses and health care utilization among Medicare beneficiaries with lung cancer[J].Crit Rev Oncol Hematol,2006,59(3):218-225.
[6]Inoue T,Shiomi H,Oh Rj.Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease:special reference to survival and radiation-induced pneumonitis[J].J Radiat Res,2015,56(4):727-734.
[7]Wang J,Cao J,Yuan S,et al.Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity[J].Int J Radiat Oncol Biol Phys,2013,85(3):798-804.
[8]Takeda A,Kunieda E,Ohashi T,et al.Severe COPD Is Correlated With Mild Radiation Pneumonitis Following Stereotactic Body Radiotherapy[J].Chest,2012,141(4):858-866.
[9]Kiri VA,Soriano J,Visick G,et al.Recent trends in lung cancer and its association with COPD:an analysis using the UK GP Research Database[J].Prim Care Respir J,2010,19(1):57-61.
[10]Gao YH,Guan W J,Liu Q,et al.Impact of COPD and emphysema on survival of patients with lung cancer:A meta-analysis of observational studies[J].Respirology,2016,21(2):269-279.
[11]Grills I S,Mangona VS,Welsh R,et al.Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer[J].J Clin Oncol,2010,28(6):928-935.
[12]Mokhles S,Verstegen N,Maat AP,et al.Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy:Results from propensity score analysis[J]Lung Cancer,2015,87(3):283-289.
[13]Eapen MS,Hansbro PM,Larsson-Callerfelt AK,et al.Chronic Obstructive Pulmonary Disease and Lung Cancer:Underlying Pathophysiology and New Therapeutic Modalities[J].Drugs,201878(16):1717-1740.
[14]Troosters T,Casaburi R,Gosselink R,et al.Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med,2005,172(1):19-38.
[15]Cavalheri V,Granger C.Preoperative exercise training for patients with non-small cell lung cancer[M].Chichester,UK:John Wiley&Sons Ltd,1996.
[16]Cavalheri V,Tahirah F,Nonoyama M,et al.Exercise training for people following lung resection for non-small cell lung cancer-a Cochrane systematic review[J].Cancer Treat Rev,2014,40(4):585-594.
[17]Wiskemann J,Hummler S,Diepold C,et al.POSITIVE study:physical exercise program in non-operable lung cancer patients undergoing palliative treatment[J].BMC Cancer,2016,16(1):16:499.
[18]Edbrooke L,Aranda S,Granger CL,et al.Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer-protocol for a phase II randomised controlled trial[J]BMC Cancer,2017,17(1):663.
[19]Sin DD,Wu L,Anderson JA,et al.Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease[J].Thorax,200560(12):992-997.
[20]R ay makers A J,Mccormick N,Marra CA,et al.Do inhaled corticosteroids protect against lung cancer in patients with COPD?Asystematic review[J].Respirology,2017,22(1):61-70.
[21]S?rensen H T,Mellemkj?r L,Olsen JH,et al.Prognosis of Cancers Associated with Venous Thromboembolism[J].N Engl J Med,2000343(25):1846-1850.
[22]Li Y,Shang Y,Wang W,et al.Lung Cancer and Pulmonary Embolism:What Is the Relationship?A Review[J].J Cancer,2018,9(17):3046-3057.
[23]Ma L,Wen Z.Risk factors and prognosis of pulmonary embolism in patients with lung cancer[J].Medicine(Baltimore),2017,96(16):e6638.
[24]Christensen T D,Vad H,Pedersen S,et al.Venous thromboembolism in patients undergoing operations for lung cancer:a systematic review[J].Ann Thorac Surg,2014,97(2):394-400.
[25]Sun JM,Kim TS,Lee J,et al.Unsuspected pulmonary emboli in lung cancer patients:the impact on survival and the significance of anticoagulation therapy[J].Lung Cancer,2010,69(3):330-336.
[26]Konstantinides SV.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J].Eur Heart J,201435(43):3033-3073.
[27]MahéI,Chidiac J,Bertoletti L,et al.The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site[J].Am JMed,2017,130(3):337-347.
[28]Shinagare A B,Ok ajima Y,Ox nard GR,et al.Unsuspected pulmonary embolism in lung cancer patients:Comparison of clinical characteristics and outcome with suspected pulmonary embolism[J].Lung Cancer,2012,78(2):161-166.
[29]Zhang J,Zhang YL,Ma KX,et al.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis[J].Thorax2013,68(5):442-450.
[30]Zhang J,Zhang YL,Ma KX,et al.Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants:a systematic review and meta-analysis[J].Thorax2013,68(5):442-450.
[31]Fuentes HE,Oramas DM,Paz LH,et al.Meta-analysi s on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer[J].Thromb Res,2017,154:28-34.
[32]Archontogeorgis K,Steiropoulos P,Tzouvelekis A,et al.Lung Cancer and Interstitial Lung Diseases:A Systematic Review[J].Pulm Med2012,2012(1):1-11.
[33]Raghu G,Nyberg F,Morgan G.The epidemiology of interstitial lung disease and its association with lung cancer[J].Br J Cancer,2004,91Suppl 2(S2):S3-10.
[34]Miyazaki K,Satoh H,Kurishima K,et al.Interstitial lung disease in patients with small cell lung cancer[J].Med Oncol,2010,27(3):763-767.
[35]Chen H,Senan S,Nossent EJ,et al.Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease:A Systematic Review[J].Int J Radiat Oncol Biol Phys,2017,98(3):622-631.
[36]Sato T,Teramukai S,Kondo H,et al.Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer[J].J Thorac Cardiovasc Surg,2014,147(5):1604-1611.
[37]Kato T,Masuda N,Nakanishi Y,et al.Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer[J].Lung Cancer,2017,104:111-118.
[38]Tomassetti S,Gurioli C,Ryu JH,et al.The Impact of Lung Cancer on Survival of Idiopathic Pulmonary Fibrosis[J].Chest,2015,147(1):157-164.
[39]Mohamed S,Bayoumi H,El-Aziz NA,et al.Prevalence,risk factors,and impact of lung Cancer on outcomes of idiopathic pulmonary fibrosis:a study from the Middle East[J].Multidiscip Respir Med,2018,13:3.